Trend Investment Group
27
4M
21
1
0.22
1
- Areas of investment
Summary
The typical case for the fund is to invest in rounds with 3-4 participants. The meaningful sponsors for the fund in investment in the same round are Oriza Seed Capital (Oriza Yuandian), Decheng Capital, Craig Fletcher. In the next rounds fund is usually obtained by South China Venture Capital, Sherpa Venture Capital, SDIC Fund Management.
Among the most popular portfolio startups of the fund, we may highlight EpimAb Biotherapeutics. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Software Engineering.
The overall number of key employees were 1.
The fund is generally included in less than 2 deals every year. The high activity for fund was in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 27
- Lead investments
- 1
- Exits
- 1
- Follow on index
- 0.22
- Investments by industry
- Biotechnology (15)
- Health Care (9)
- Biopharma (5)
- Medical (5)
- Therapeutics (5) Show 45 more
- Investments by region
-
- United Kingdom (18)
- China (5)
- United States (4)
- Peak activity year
- 2017
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 191M
- Group Appearance index
- 0.37
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| DataClue Genomics | 01 Aug 2021 | Artificial Intelligence, Machine Learning, Health Care, Genetics, Medical, Health Insurance, Life Science | Seed | 2M | England, London, United Kingdom |
| PhoreMost | 23 Mar 2021 | Biotechnology, Health Care, Biopharma | Early Stage Venture | 45M | England, Cambridge, United Kingdom |
| Senisca | 18 Mar 2024 | Biotechnology | Seed | 5M | England, Exeter, United Kingdom |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.